Sugi Predict

Sugi Predict / Compounds / SCHEMBL6190071

SCHEMBL6190071

SCHEMBL6190071

Cc1n(Cc2cnccn2)c2c([n+]1Cc1cnccn1)C(=O)c1ccccc1C2=O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BIRC5 O15392 1/20 0.74
▸ RIPK2 O43353 1/20 0.74
▸ SP1 P08047 1/20 0.74
▸ ILF3 Q12906 1/20 0.74
▸ PAK1 Q13153 1/20 0.74
▸ GABRA1 P14867 1/20 0.41
▸ GABRA5 P31644 1/20 0.41
▸ CYP1B1 Q16678 1/20 0.39
▸ GRIN1 Q05586 5/20 0.36
▸ GRIN2B Q13224 5/20 0.36
▸ KCNK13 Q9HB14 1/20 0.34
▸ IDO1 P14902 1/20 0.34
▸ TLR7 Q9NYK1 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ TDP2 O95551 2/20 0.32
▸ TDP1 Q9NUW8 2/20 0.32
▸ TBXAS1 P24557 1/20 0.32
▸ MAOA P21397 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sepantronium SCHEMBL2814447 0.86 BIRC5 (0.98) BIRC5RIPK2SP1ILF3PAK1
Sepantronium SCHEMBL2814857 0.86 BIRC5 (0.98) BIRC5RIPK2SP1ILF3PAK1
Sepantronium SCHEMBL29464041 0.86 BIRC5 (0.71) BIRC5RIPK2SP1ILF3PAK1
Sepantronium SCHEMBL6188375 0.86 BIRC5 (0.71) BIRC5RIPK2SP1ILF3PAK1
Sepantronium SCHEMBL29379252 0.86 BIRC5 (0.73) BIRC5RIPK2SP1ILF3PAK1
Sepantronium SCHEMBL16584072 0.86 BIRC5 (0.73) BIRC5RIPK2SP1ILF3PAK1
Sepantronium SCHEMBL727997 0.86 BIRC5 (1.00) BIRC5RIPK2SP1ILF3PAK1
Sepantronium SCHEMBL29493286 0.86 BIRC5 (1.00) BIRC5RIPK2SP1ILF3PAK1
Bromide SCHEMBL22413046 0.83 BIRC5 (0.61) BIRC5RIPK2SP1ILF3PAK1
Bromide SCHEMBL15062823 0.76 BIRC5 (0.79) BIRC5RIPK2SP1ILF3PAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1256576-B1 FUSED IMIDAZOLIUM DERIVATIVES YAMANOUCHI PHARMA CO LTD (JP) 2005-06-15 — — EP claimed
US-6734203-B2 ANTI-CANCERS AND ANTITUMOR AGENTS ASTELLAS PHARMA INC. (JP) 2004-05-11 — — US claimed
US-20030114508-A1 Fused imidazolium derivatives ASTELLAS PHARMA INC. (JP) 2003-06-19 — — US claimed
EP-1256576-A1 FUSED IMIDAZOLIUM DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2002-11-13 — — EP claimed
EP-1256576-B1 FUSED IMIDAZOLIUM DERIVATIVES YAMANOUCHI PHARMA CO LTD (JP) 2005-06-15 — — EP disclosed
US-6734203-B2 ANTI-CANCERS AND ANTITUMOR AGENTS ASTELLAS PHARMA INC. (JP) 2004-05-11 — — US disclosed
US-20030114508-A1 Fused imidazolium derivatives ASTELLAS PHARMA INC. (JP) 2003-06-19 — — US disclosed
EP-1256576-A1 FUSED IMIDAZOLIUM DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2002-11-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114508-A1 Fused imidazolium derivatives TP53, HRAS, BCOR BIRC5 53/4885RIPK2 408/4885SP1 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.